Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Net Income (2016 - 2025)

Historic Net Income for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $124.8 million.

  • BeOne Medicines' Net Income rose 20287.68% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 10796.67%. This contributed to the annual value of -$644.8 million for FY2024, which is 2687.08% up from last year.
  • BeOne Medicines' Net Income amounted to $124.8 million in Q3 2025, which was up 20287.68% from $94.3 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Net Income peaked at $215.4 million during Q3 2023, and registered a low of -$590.7 million during Q4 2021.
  • Moreover, its 5-year median value for Net Income was -$348.4 million (2023), whereas its average is -$250.1 million.
  • As far as peak fluctuations go, BeOne Medicines' Net Income crashed by 75448.23% in 2022, and later surged by 20287.68% in 2025.
  • Over the past 5 years, BeOne Medicines' Net Income (Quarter) stood at -$590.7 million in 2021, then increased by 24.61% to -$445.3 million in 2022, then increased by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then surged by 182.2% to $124.8 million in 2025.
  • Its Net Income was $124.8 million in Q3 2025, compared to $94.3 million in Q2 2025 and $1.3 million in Q1 2025.